Homepage
Author:
Palvella Therapeutics Inc.
Posted Date:
April 13, 2026
Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
Palvella Therapeutics Inc.
April 13, 2026
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
Palvella Therapeutics Inc.
April 7, 2026
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Palvella Therapeutics Inc.
March 31, 2026
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations
Palvella Therapeutics Inc.
March 30, 2026
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
Palvella Therapeutics Inc.
March 27, 2026
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026
Palvella Therapeutics Inc.
March 24, 2026
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
Palvella Therapeutics Inc.
March 23, 2026
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
Palvella Therapeutics Inc.
March 16, 2026
Palvella Therapeutics Launches “BEYOND mLM” Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations
Palvella Therapeutics Inc.
March 10, 2026
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Palvella Therapeutics Inc.
March 2, 2026
1
2
Next
